Results 371 to 380 of about 3,443,356 (396)

PARP inhibitors in ovarian cancer

Seminars in Oncology
Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency.
Ian S. Goldlust, Elena Guidice, Jung-min Lee   +2 more
openaire   +2 more sources

PARP inhibitors plough on

Nature Reviews Drug Discovery, 2017
openaire   +2 more sources

PARP Inhibitors

2014
Joaquin Mateo, Timothy A. Yap, Johann S. De Bono   +2 more
openaire   +1 more source

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Cell Chemical Biology, 2022
Vinayak Palve, Daniel S Bejan, Alvaro N A Monteiro   +2 more
exaly  

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology, 2022
Jing Wang, Chong Lu, Yu Kang
exaly  

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Cancers, 2020
Elizabeth K Lee, Ursula A Matulonis
exaly  

PARP inhibitors: pitfalls and promises

The Lancet Oncology, 2013
Jeffrey R, Infante, Howard A, Burris
openaire   +2 more sources

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell, 2018
Ewa Gogola, Wouter W Wiegant, Daniel J Vis   +2 more
exaly  

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

EBioMedicine, 2018
Chenying Li, Jiansong Huang, Xin Huang   +2 more
exaly  

<p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>

Cancer Management and Research, 2019
Xuan Jiang, Weihua Li, Huimin Bai
exaly